New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab
ÌÇÐÄ´«Ã½
Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab CLINICAL LYMPHOMA Natkunam, Y., Stanton, T. S., Warnke, R. A., Horning, S. J. 2001; 2 (3): 185-187Abstract
A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma. While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's and non-Hodgkin's lymphomas from which they must be distinguished for diagnosis and treatment. We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab.
View details for
View details for